Drugs / MK0524A
last change Sep 2010 re-read 2 minutes ago

MK0524A

Developed for
flushing of ears and somnolence · hyperlipidemia · hyperlipidemia, combined, 2 · hyperlipoproteinemia
Investigated by
Merck Sharp & Dohme LLC

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 23 trials
Phase 2 NCT00533312 Apr → Jul 2005 hyperlipidemia Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 2 NCT00536237 Aug 2004 → Feb 2005 flushing of ears and somnolence Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 2 NCT00533676 Aug 2004 → Dec 2006 flushing of ears and somnolence Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 34 trials
Phase 3 NCT00479882 Jun 2007 → Jun 2008 hyperlipidemia, combined, 2, hyperlipoproteinemia Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 3 NCT00533611 Apr → Aug 2007 flushing of ears and somnolence Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 3 NCT00376584 Jul 2006 → Jan 2007 hyperlipidemia Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 3 NCT00289900 Jan 2006 → Aug 2010 hyperlipidemia, combined, 2 Merck Sharp & Dohme LLC Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT00738985 Comparator Nov 2009 → Sep 2010 cardiovascular disorder, hyperlipidemia National Institute of Medical Sciences and Nutrition Salvador Zubiran Withdrawn No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as MK-0524A ClinicalTrials.gov intervention name — accepted as the source's own label NCT00479882
7

NCT00536237

NCT00533611

NCT00533676

NCT00533312

NCT00376584

NCT00738985

NCT00289900